NTLA-2001
Phase 3Biologic
Intellia TherapeuticsNTLA-2001 is one of 31 biologic programs targeting Cardiomyopathy. It is currently in Phase 3.
1
Indications
2
Total Trials
1
Active Trials
30
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
37 competitors in Cardiomyopathy
#DrugCompanyPhaseTrials
1Ozempic
Novo NordiskApproved
Bayer Aspirin
BayerApproved
Rayos
RRoxane Laboratories
Approved
Inspra
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Zocor
OOrganon and Co
Approved
Cordarone
WWyeth-Lederle Vaccines
Approved
Imuran
LLegacy Health System
Approved
Brevibloc
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Approved
Inpefa
LLexicon Pharmaceuticals
Approved
Lipitor
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Cardiomyopathy1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for NTLA-2001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Phase 3[1]
- Company